Category Archives: Oncology

The telomerase inhibitor Imetelstat developed by Geron

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Brigham and Women’s Hospital engages in bizarre PR campaign for daily aspirin

 April 21, 2015- By Steven E. Greer, MD Brigham and Women’s Hospital in Boston, part of the Harvard University network of hospitals,

Posted in - Policy, Cardiology, Harvard, Neurology, Oncology | Leave a comment

Daily aspirin once again proves to be of no use and also deadly

Update January 13, 2015- Yet another study was published highlighting the risks of daily aspirin. 

Posted in - JAMA, - Pharma, - Policy, Cardiac surgery, Cardiology, Gastroenterology and liver, General surgery, Neurology, Neurosurgery, Oncology, Primary care medicine | Leave a comment

Exclusive: CEO of Komen for the Cure never stepped down as announced in 2012

June 6, 2013- By Steven E. Greer, MD The breast cancer research foundation Komen for the Cure, founded by Nancy Brinker, got into hot water in 2012

Posted in - Policy, Oncology | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Steven E. Greer MD: A discussion with Bill O’Reilly about radiation risks

April 1, 2011- A discussion with Bill O’Reilly about radiation risks from the Fukushima nuclear meltdowns and the fallout hitting the U.S. and entire globe.

Posted in - Policy, Congress, NYU, Ohio State, Oncology | Leave a comment

Paul Richardson, MD: Three-drug regimen for multiple myeloma

December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Early palliative care improves outcomes in lung cancer patients

August 30, 2010- Produced and interviewed by Steven Greer, MD A group from Harvard published a paper in The NEJM that showed early initiation of palliative

Posted in Harvard, Oncology | Leave a comment

The unsustainable cost of cancer drugs

June 8, 2009- Interviewed by Steven Greer, MD Leonard Saltz, MD, of Memorial Sloan-Kettering Cancer Center, discusses how the targeted

Posted in - Opinion, - Policy, Congress, Memorial Sloan-Kettering, Oncology | Leave a comment